Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second. Demand for Eli Lilly's Mounjaro and Zepbound remains robust, and sell-side analysts tracking script data shows strong growth for both of these drugs.
Eli Lilly & Co: Buy Rating Justified Despite Short-Term Sales Miss
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 568.82% and currently trading at $884.25. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Momentum Stock Now
Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
In a report released today, Carter Gould from Barclays maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a
Hoodline
12h
Michigan Attorney General Fights to Revoke Decades-Old Rulings Shielding Pharma Giant Eli Lilly from Insulin Pricing Scrutiny
Michigan's Supreme Court reexamines rulings that may affect how the state's consumer protection laws apply to insulin pricing ...
22h
on MSN
Novo and Lilly contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...
1d
Eli Lilly and Company (NYSE:LLY) Shares Up 2.3% – Here’s What Happened
Eli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.3% on Tuesday . The company traded as high as $920.28 and ...
1d
AG, Eli Lilly spar before the Michigan Supreme Court over insulin pricing investigation
The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...
1d
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
22h
Eli Lilly and Company (NYSE:LLY) Shares Sold by Sanibel Captiva Trust Company Inc.
Sanibel Captiva Trust Company Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.8% ...
1d
Knockoff weight loss drug sellers are fighting back against Eli Lilly and the FDA
Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...
8d
on MSN
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
STAT
2d
Eli Lilly, Insitro ink a new kind of AI drug development deal
Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic ...
ABC News
9d
Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements
Eli
Lilly
is pouring another $4.5 billion into ... drug development a few miles from its Indianapolis headquarters. The
company
said its
Lilly
Medicine Foundry will allow it to both research ...
FierceBiotech
4d
AstraZeneca pays CSPC $100M for preclinical heart disease drug, teeing up combos and Lilly rivalry
AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zepbound
New York Stock Exchange
Novo Nordisk
Michigan Supreme Court
Glucagon-like peptide-1
Feedback